- Home
- ENTA vs GGT Comparison
ENTA vs GGT Comparison
Compare ENTA & GGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTA
- GGT
- Stock Information
- Founded
- ENTA 1995
- GGT 1994
- Country
- ENTA United States
- GGT United States
- Employees
- ENTA N/A
- GGT N/A
- Industry
- ENTA Biotechnology: Pharmaceutical Preparations
- GGT Trusts Except Educational Religious and Charitable
- Sector
- ENTA Health Care
- GGT Finance
- Exchange
- ENTA Nasdaq
- GGT Nasdaq
- Market Cap
- ENTA 164.6M
- GGT 134.4M
- IPO Year
- ENTA 2013
- GGT N/A
- Fundamental
- Price
- ENTA $7.51
- GGT $4.26
- Analyst Decision
- ENTA Buy
- GGT
- Analyst Count
- ENTA 5
- GGT 0
- Target Price
- ENTA $18.40
- GGT N/A
- AVG Volume (30 Days)
- ENTA 173.3K
- GGT 59.7K
- Earning Date
- ENTA 08-08-2025
- GGT 01-01-0001
- Dividend Yield
- ENTA N/A
- GGT 15.56%
- EPS Growth
- ENTA N/A
- GGT N/A
- EPS
- ENTA N/A
- GGT 0.83
- Revenue
- ENTA $64,462,999.00
- GGT N/A
- Revenue This Year
- ENTA N/A
- GGT N/A
- Revenue Next Year
- ENTA $2.75
- GGT N/A
- P/E Ratio
- ENTA N/A
- GGT $6.90
- Revenue Growth
- ENTA N/A
- GGT N/A
- 52 Week Low
- ENTA $4.09
- GGT $4.32
- 52 Week High
- ENTA $15.92
- GGT $7.00
- Technical
- Relative Strength Index (RSI)
- ENTA 51.19
- GGT 56.28
- Support Level
- ENTA $7.15
- GGT $4.19
- Resistance Level
- ENTA $8.31
- GGT $4.32
- Average True Range (ATR)
- ENTA 0.48
- GGT 0.05
- MACD
- ENTA 0.01
- GGT -0.01
- Stochastic Oscillator
- ENTA 55.73
- GGT 56.31
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
About GGT Gabelli Multi-Media Trust Inc. (The)
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.